From: ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis—a EUSTAR analysis
No. of renal crises/patients | Hazard ratio (95% CI) | P value | |
---|---|---|---|
Age (per decade) | 78/6083 | 1.06 (0.87–1.28) | 0.56 |
Sex (male) | 1.30 (0.74–2.28) | 0.36 | |
Diffuse skin involvement | 1.79 (1.06–3.02) | 0.030 | |
Time since onset of scleroderma (per decade) | 0.77 (0.55–1.08) | 0.13 | |
Arterial hypertension | 2.22 (1.34–3.66) | 0.002 | |
Tendon friction rub | 1.70 (0.83–3.48) | 0.15 | |
ACE inhibitors | 2.07 (1.28–3.36) | 0.003 | |
SCL70-positive | 0.98 (0.58–1.66) | 0.94 | |
ACA-positive | 0.82 (0.45–1.49) | 0.52 | |
Glucocorticoids > 10 mg | 1.49 (0.53–4.17) | 0.45 | |
PDE5 inhibitors | 1.32 (0.60–2.87) | 0.49 |